Trials / Completed
CompletedNCT01800695
Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 202 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This study is evaluating the safety and pharmacokinetics of ABT-414 in subjects with glioblastoma multiforme.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-414 | ABT-414 will be administered by intravenous infusion |
| DRUG | Temozolomide | Temozolomide will be administered per label and local prescribing regulations. |
| RADIATION | Whole Brain Radiation | Whole Brain radiation will be administered in 30 fractions. |
Timeline
- Start date
- 2013-04-02
- Primary completion
- 2017-06-19
- Completion
- 2017-06-19
- First posted
- 2013-02-28
- Last updated
- 2017-11-21
Source: ClinicalTrials.gov record NCT01800695. Inclusion in this directory is not an endorsement.